Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.

Harding T, Baughn L, Kumar S, Van Ness B.

Leukemia. 2019 Jan 25. doi: 10.1038/s41375-018-0362-z. [Epub ahead of print] Review.

PMID:
30683909
2.

Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, Baughn LB, Van Ness B, Rajkumar V, Kumar S, Jen J.

Blood Cancer J. 2019 Jan 3;9(1):2. doi: 10.1038/s41408-018-0160-x.

3.

Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants.

Wolf SM, Scholtes E, Koenig BA, Petersen GM, Berry SA, Beskow LM, Daly MB, Fernandez CV, Green RC, LeRoy BS, Lindor NM, O'Rourke PP, Breitkopf CR, Rothstein MA, Van Ness B, Wilfond BS.

J Law Med Ethics. 2018 Mar;46(1):87-109. doi: 10.1177/1073110518766024. Epub 2018 Mar 27. No abstract available.

4.

EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.

Harding T, Swanson J, Van Ness B.

Oncotarget. 2018 Apr 24;9(31):21930-21942. doi: 10.18632/oncotarget.25128. eCollection 2018 Apr 24.

5.

Development of expression-based biomarkers of Dasatinib response in hematologic malignancies.

Akre MK, Mitra A, Wang W, Myers CL, Van Ness B.

Blood Cancer J. 2017 Dec 15;7(12):652. doi: 10.1038/s41408-017-0013-z. No abstract available.

6.

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, Kumar S, Kuehl WM, Rajkumar V, Van Ness B.

Blood Cancer J. 2017 Jun 30;7(6):e581. doi: 10.1038/bcj.2017.56.

7.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG.

Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.

8.

A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.

Mitra AK, Dodge J, Van Ness J, Sokeye I, Van Ness B.

Mol Genet Genomic Med. 2016 Dec 26;5(2):130-140. doi: 10.1002/mgg3.265. eCollection 2017 Mar.

9.

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.

Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA.

Leuk Lymphoma. 2017 Aug;58(8):1931-1940. doi: 10.1080/10428194.2016.1266621. Epub 2016 Dec 16.

10.

Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate.

Mitra AK, Stessman HA, Schaefer RJ, Wang W, Myers CL, Van Ness BG, Beiraghi S.

Front Genet. 2016 May 23;7:88. doi: 10.3389/fgene.2016.00088. eCollection 2016.

11.

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP.

Cell Rep. 2016 Jun 7;15(10):2266-2278. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26.

12.

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, Kumar S, Rajkumar V, Van Ness B.

Leukemia. 2016 May;30(5):1094-102. doi: 10.1038/leu.2015.361. Epub 2015 Dec 29.

PMID:
26710886
13.
14.

Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations.

Wolf SM, Branum R, Koenig BA, Petersen GM, Berry SA, Beskow LM, Daly MB, Fernandez CV, Green RC, LeRoy BS, Lindor NM, O'Rourke PP, Breitkopf CR, Rothstein MA, Van Ness B, Wilfond BS.

J Law Med Ethics. 2015 Fall;43(3):440-63. doi: 10.1111/jlme.12288.

15.

Risk of multiple myeloma in a case-spouse study.

Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B.

Leuk Lymphoma. 2016;57(6):1450-9. doi: 10.3109/10428194.2015.1094693. Epub 2015 Nov 16.

PMID:
26422532
16.

Applications and limitations in translating genomics to clinical practice.

Van Ness B.

Transl Res. 2016 Feb;168:1-5. doi: 10.1016/j.trsl.2015.04.012. Epub 2015 May 4. Review.

PMID:
26001594
17.

Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.

Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA.

J Cancer. 2014 Sep 21;5(9):720-7. doi: 10.7150/jca.9864. eCollection 2014. Review.

18.

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG.

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. No abstract available.

PMID:
25005244
19.

Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.

Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB.

PLoS One. 2013 Oct 29;8(10):e77608. doi: 10.1371/journal.pone.0077608. eCollection 2013.

20.

Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency.

Stessman HA, Mansoor A, Linden MA, Van Ness B, Baughn LB.

Leuk Lymphoma. 2014 Jan;55(1):220-2. doi: 10.3109/10428194.2013.797575. Epub 2013 Jun 4. No abstract available.

PMID:
23734619
21.

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B.

Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14. No abstract available.

22.

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.

23.

High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions.

Fang G, Haznadar M, Wang W, Yu H, Steinbach M, Church TR, Oetting WS, Van Ness B, Kumar V.

PLoS One. 2012;7(4):e33531. doi: 10.1371/journal.pone.0033531. Epub 2012 Apr 19.

24.

Managing incidental findings and research results in genomic research involving biobanks and archived data sets.

Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, Cho MK, Christman MF, Green RC, Hall R, Illes J, Keane M, Knoppers BM, Koenig BA, Kohane IS, Leroy B, Maschke KJ, McGeveran W, Ossorio P, Parker LS, Petersen GM, Richardson HS, Scott JA, Terry SF, Wilfond BS, Wolf WA.

Genet Med. 2012 Apr;14(4):361-84. doi: 10.1038/gim.2012.23.

25.
26.

Return of individual research results and incidental findings in the clinical trials cooperative group setting.

Ferriere M, Van Ness B.

Genet Med. 2012 Apr;14(4):411-6. doi: 10.1038/gim.2012.14. Epub 2012 Mar 1.

27.

Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Linden MA, Kirchhof N, Carlson CS, Van Ness BG.

Exp Hematol. 2012 Mar;40(3):216-27. doi: 10.1016/j.exphem.2011.11.006. Epub 2011 Nov 23.

28.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.

29.

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ.

J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.

PMID:
21245421
30.

Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.

Minarik J, Scudla V, Ordeltova M, Pika T, Bacovsky J, Steinbach M, Kumar V, Van Ness B.

Leuk Res. 2011 Jan;35(1):44-8. doi: 10.1016/j.leukres.2010.04.015. Epub 2010 May 21.

PMID:
20488540
31.

Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk.

Church TR, Haznadar M, Geisser MS, Anderson KE, Caporaso NE, Le C, Abdullah SB, Hecht SS, Oken MM, Van Ness B.

Int J Mol Epidemiol Genet. 2010 Aug 5;1(4):295-309.

32.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1. Review.

33.

Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.

Durie BG, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA, Morgan GJ, Crowley J, Barlogie B, Shaughnessy J Jr.

Leukemia. 2009 Oct;23(10):1913-9. doi: 10.1038/leu.2009.129. Epub 2009 Aug 6.

34.

Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.

Khuda SE, Loo WM, Janz S, Van Ness B, Erickson LD.

J Immunol. 2008 Dec 1;181(11):7537-49.

35.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ.

Blood. 2008 Dec 15;112(13):4924-34. doi: 10.1182/blood-2008-02-140434. Epub 2008 Sep 19.

36.

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.

Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G.

BMC Med. 2008 Sep 8;6:26. doi: 10.1186/1741-7015-6-26.

37.

Genomic research and incidental findings.

Van Ness B.

J Law Med Ethics. 2008 Summer;36(2):292-7, 212. doi: 10.1111/j.1748-720X.2008.00272.x.

38.

Managing incidental findings in human subjects research: analysis and recommendations.

Wolf SM, Lawrenz FP, Nelson CA, Kahn JP, Cho MK, Clayton EW, Fletcher JG, Georgieff MK, Hammerschmidt D, Hudson K, Illes J, Kapur V, Keane MA, Koenig BA, Leroy BS, McFarland EG, Paradise J, Parker LS, Terry SF, Van Ness B, Wilfond BS.

J Law Med Ethics. 2008 Summer;36(2):219-48, 211. doi: 10.1111/j.1748-720X.2008.00266.x. Review.

39.

Clinical and biological significance of RAS mutations in multiple myeloma.

Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R.

Leukemia. 2008 Dec;22(12):2280-4. doi: 10.1038/leu.2008.142. Epub 2008 Jun 5. No abstract available.

40.

A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.

Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG.

Cancer Res. 2007 May 1;67(9):4069-78.

41.

The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Morgan KJ, Rowley MA, Wiesner SM, Hasz DE, Van Ness B, Largaespada DA.

Leuk Res. 2007 Aug;31(8):1107-13. Epub 2007 Jan 12.

42.

Clinical significance of TP53 mutation in myeloma.

Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R.

Leukemia. 2007 Mar;21(3):582-4. Epub 2007 Jan 11. No abstract available.

PMID:
17215851
43.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R.

Blood. 2007 Feb 1;109(3):1228-32. Epub 2006 Jul 13.

44.
46.

ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.

Linden M, Kirchhof N, Kvitrud M, Van Ness B.

Leuk Res. 2005 Apr;29(4):435-44. Epub 2004 Dec 18.

PMID:
15725478
47.

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S.

J Clin Invest. 2004 Jun;113(12):1763-73.

48.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation.

Hematol J. 2003;4(6):379-98. Review. Erratum in: Hematol J. 2004;5(3):285.

PMID:
14671610
49.

Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.

Linden M, Kirchhof N, Carlson C, Van Ness B.

Blood. 2004 Apr 1;103(7):2779-86. Epub 2003 Dec 4.

50.

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.

Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A.

Mol Cancer Ther. 2003 Jun;2(6):563-72.

Supplemental Content

Loading ...
Support Center